A high level of methylated O6-methylguanine-DNA methyltransferase promoter methylation is associated with a favorable outcome of medulloblastoma [33], loss of 5hmC correlates with adverse prognosis in WHO grade II diffuse astrocytomas [34], while EZH2 expression has been described as an independent marker of poor prognosis in pediatric ependymoma [35]. The gene discussed is EZH2; the disease is medulloblastoma.